Compare

CBL-514 vs Liraglutide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

CBL-514

1416 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 60% · Mixed 32% · Unfavorable overall 8%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Digestive comfort
91
Skin appearance
111
Appetite control
136
Energy
95
Mood
44

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Flushing
187
Headache
191
GI discomfort
101
Dizziness
90
Fatigue
44

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 0–1000 mcg

0–10
2
10–25
6
25–50
11
50–100
17
100–200
28
200–400
19
400–600
11
600–1000
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing20stacking38side effects26cbl-51424

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 312 repeat reporters

Liraglutide

2186 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 50% · Mixed 40% · Unfavorable overall 10%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Sleep quality
-143
Lean mass
-120
Joint comfort
-72
Recovery
-111
Digestive comfort
-26

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Water retention
-47
Appetite loss
-41
Injection site reaction
-108
Anxiety
-116
Flushing
-27

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.05–3 mg

0.05–0.1 mg
9
0.1–0.2 mg
17
0.2–0.4 mg
20
0.4–0.6 mg
25
0.6–1 mg
17
1–2 mg
14
2–3 mg
9

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing30stacking43side effects16liraglutide19

How repeat users are trending

Among repeat reporters, 60% said they felt similar to their last entry, 30% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 19 days · Based on 481 repeat reporters

Sources (19)

Published sources linked on the CBL-514 and Liraglutide wiki pages.

  1. PubMed

    Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study

    Gold M, Schlessinger J, Goodman GJ, et al. Aesthetic Surgery Journal. 2025

    Source
    Wiki study page →
  2. PubMed

    Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment

    Lorenc ZP, Gold M, Schlessinger J, et al. Aesthetic Surgery Journal. 2026

    Source
    Wiki study page →
  3. PubMed

    Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction

    Goodman GJ, Ho WWS, Chang KJ, et al. Aesthetic Surgery Journal. 2022

    Source
    Wiki study page →
  4. PubMed

    Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study

    Herbst KL, Ling YF, Sheu AY, et al. JAAD International. 2026

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    SUPREME-01 (NCT07140939): Phase 3 CBL-514 for abdominal subcutaneous fat

    ClinicalTrials.gov. Clinical trial registry. 2026

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    SUPREME-02 (NCT07526974): Phase 3 CBL-514 for abdominal subcutaneous fat

    ClinicalTrials.gov. Clinical trial registry. 2026

    Source
    Wiki study page →
  7. Manufacturer

    Caliway Announces First Patient Dosed in Global Phase 3 SUPREME-01 Trial of CBL-514

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  8. Manufacturer

    Caliway Highlights Global Phase 3 Progress and GLP-1 Combination Strategy (Aug 31, 2026 Investor Conference)

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  9. Manufacturer

    Caliway Completes U.S. FDA IND Submission for SUPREME-02 Phase 3 Study of CBL-514

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  10. FDA Drug Label

    KYBELLA (deoxycholic acid) injection — Prescribing Information

    Allergan. FDA Drug Label. 2015

    Source
    Wiki study page →
  11. Review Article

    An experimental drug kills fat cells, rather than shrinking them

    Tina Hesman Saey, Science News. Science News. 2026

    Source
    Wiki study page →
  12. Review Article

    CBL-514 injection reduces visceral and subcutaneous fat in trials

    News-Medical.net. Conference news summary. 2026

    Source
    Wiki study page →
  13. FDA Drug Label

    SAXENDA (liraglutide) injection — Prescribing Information

    Novo Nordisk. FDA Drug Label. 2014

    Source
    Wiki study page →
  14. FDA Drug Label

    VICTOZA (liraglutide) injection — Prescribing Information

    Novo Nordisk. FDA Drug Label. 2010

    Source
    Wiki study page →
  15. PubMed

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial)

    Marso SP, Daniels GH, Brown-Frandsen K, et al. N Engl J Med. 2016

    Source
    Wiki study page →
  16. PubMed

    A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)

    Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med. 2015

    Source
    Wiki study page →
  17. PubMed

    Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

    Rubino DM, Greenway FL, Khalid U, et al. JAMA. 2022

    Source
    Wiki study page →
  18. PubMed

    Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

    Garvey WT, Birkenfeld AL, Dicker D, et al. Diabetes care. 2020

    Source
    Wiki study page →
  19. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →